vimarsana.com
Home
Live Updates
Freya Pharma Solutions Announces Response from the FDA on its US Clinical Development Program of LybridoTM for the treatment of Female Sexual Interest/Arousal Disorder : vimarsana.com
Freya Pharma Solutions Announces Response from the FDA on its US Clinical Development Program of LybridoTM for the treatment of Female Sexual Interest/Arousal Disorder
/PRNewswire/ -- Freya Pharma Solutions, a pharmaceutical company dedicated to developing effective pharmaceutical therapies for women diagnosed with Female...
Related Keywords
Amsterdam ,
Noord Holland ,
Netherlands ,
United States ,
American ,
Marcel Wijma ,
Freya Pharma ,
Us Clinical Development Program Of Lybrido ,
Drug Administration ,
Freya Pharma Solutions ,
American Psychiatric Association ,
Lifespring Life Sciences Communication ,
Female Sexual Disorders ,
Development Program ,
Female Sexual ,
Arousal Disorder ,
European Medicines ,
Scientific Advisory Board ,
Marketing Authorization Application ,
Chief Medical Officer ,
Sexual Desire Disorder ,
Statistical Manual ,
Mental Disorders ,
Pharma Solutions ,
Chief Executive ,
Spring Life Sciences Communication ,
vimarsana.com © 2020. All Rights Reserved.